HLP003, a deuterated form of psilocin developed by Helus Pharma, met its primary endpoint in the Phase 3 APPROACH trial in major depressive disorder, the company reported on November 16, 2026. Added to patients’ existing antidepressants, a single course of HLP003 cut depression scores by 7.6 points more than placebo at week 6 (p<0.0001), with half of treated patients in remission by that point, and the benefit was still visible at week 12.
Key takeaways on HLP003
- APPROACH enrolled 222 adults with moderate to severe depression (112 on HLP003, 110 on placebo) who stayed on their usual antidepressant.
- Week 6 MADRS reduction: 19.5 points with HLP003 vs 11.9 with placebo, a 7.6-point gap (p<0.0001).
- Effects appeared by day 2 and held at week 12 (7.0-point gap, p<0.0001).
- Remission at week 6: 50.9% vs 18.2%.
- Three serious adverse events were judged treatment related; a second pivotal trial, EMBRACE, reads out in Q4 2027.
The numbers from APPROACH
Depression severity was measured on the MADRS scale, where scores of 24 or more were required to enter and the average starting score was about 33. A remission is a score of 10 or less. Here is how the two arms compared, based on the company’s topline release.
| Timepoint | MADRS drop: HLP003 vs placebo | Response (50%+ drop) | Remission (MADRS 10 or less) |
|---|---|---|---|
| Day 2 | 16.1 vs 11.0 (p=0.0013) | 50.0% vs 23.6% | 39.3% vs 15.5% |
| Week 6 (primary) | 19.5 vs 11.9 (p<0.0001) | 56.3% vs 28.2% | 50.9% vs 18.2% |
| Week 12 | 16.9 vs 9.9 (p<0.0001) | 45.5% vs 19.1% | 40.2% vs 15.5% |
By our calculation, the week 6 remission figures imply a number needed to treat of about 3: for roughly every three people given HLP003 instead of placebo, one extra person reached remission. For context, a placebo-adjusted gap of 2 to 3 MADRS points is typical for daily oral antidepressants in registration trials, so a 7.6-point gap is large, although cross-trial comparisons are imperfect.
How a deuterated psilocin is supposed to work
Psilocybin, the compound in so-called magic mushrooms, is a prodrug: the body converts it into psilocin, which acts on serotonin 5-HT2A receptors. HLP003 skips that step and swaps some hydrogen atoms for deuterium, a heavier form of hydrogen. Deuteration can slow how quickly the liver breaks a molecule down, and developers of this approach aim for more predictable blood levels and a shorter, more manageable psychedelic session than with psilocybin. Helus classes the drug as a novel serotonergic agonist. It has FDA Breakthrough Therapy designation for major depressive disorder.
The caveats
- Blinding. Psychedelics produce obvious effects, so many participants likely knew which arm they were in, which can inflate the placebo-adjusted gap. Topline data do not say how this was handled.
- Safety detail is thin. Helus reported mostly mild to moderate, short-lived side effects concentrated on dosing day, plus three treatment-related serious adverse events, but no event rates or dropouts yet.
- Dose and regimen used in APPROACH were not disclosed in the release.
- One trial. FDA normally wants two adequate studies; EMBRACE, the second pivotal trial, is not due until Q4 2027.
Roger McIntyre of the University of Toronto, who commented on the results, called the magnitude of benefit “highly compelling.” Full data are expected at a medical meeting or in a journal.
Where HLP003 sits in the psychedelic race
Compass Pathways has already completed its new drug application for COMP360 psilocybin in treatment-resistant depression. HLP003 targets a broader group, people with moderate to severe depression who are already on an antidepressant, which could be a larger market if approved. Helus reported $171.1 million in cash at September 30, 2026 and plans a Phase 2 trial in generalised anxiety disorder (HLP004) in early 2027.
On market size, Acumen Research and Consulting estimated the global psychedelic drugs market at USD 2.6 billion in 2022 and projects USD 7.1 billion by 2032, a 10.9% compound annual growth rate, with North America dominant and Asia-Pacific growing fastest. The report was last updated in April 2023, before any psychedelic therapy had cleared Phase 3, so the forecast is indicative.
What it means for patients in India
Psilocybin and psilocin are controlled substances in India under the NDPS Act, and no psychedelic medicine is approved by CDSCO. Any Indian access would require separate regulatory and legal pathways, so HLP003 is not something patients can seek out today. People with depression should continue treatment with their psychiatrist and not self-medicate with mushrooms or unregulated products.
FAQ
What is HLP003?
HLP003 is an investigational deuterated psilocin from Helus Pharma, tested as an add-on to standard antidepressants in major depressive disorder. It is not approved.
How well did HLP003 work in Phase 3?
It reduced MADRS scores by 7.6 points more than placebo at week 6, and 50.9% of patients were in remission vs 18.2% on placebo.
Is HLP003 the same as psilocybin?
No. Psilocybin is converted into psilocin in the body. HLP003 is a modified psilocin with deuterium atoms, intended to give more controlled effects.
When could HLP003 be approved?
No filing date has been given. The second pivotal trial, EMBRACE, reports in Q4 2027, so a US decision is unlikely before 2028.
More trial news: Clinical Trials | Talkiatry expands mental health care to all 50 states
Sources: Helus Pharma topline APPROACH results and Q2 fiscal 2027 report (November 16, 2026). Market data from Acumen Research and Consulting, Psychedelic Drugs Market report. Not medical or investment advice. Last updated November 16, 2026.
